Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Slowdown in Covid-19 sales will further move Pfizer to M&A

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 26, 2022 11:11am

140 Views

Post# 35049746

RE:RE:RE:RE:Slowdown in Covid-19 sales will further move Pfizer to M&A

Last year, many on Wall Street were estimating the number of COVID-19 shots would be in line with the annual flu vaccine, now the slowing pace of the early COVID revaccination campaigns - particularly in the key U.S. market - is changing that view.

A recent poll by Kaiser Family Foundation found that two-thirds of American adults do not plan on getting a COVID vaccine soon. Analysts are expecting the U.S. market to be as low as one-third the size of the flu. The companies could make up for some of the weaker demand with price increases.

Investors have already started to sour on the promise of the COVID vaccine market, particularly for Moderna, BioNTech and Novavax, three young companies that rely on the shots to generate virtually all of their profits. Shares in all three companies have fallen by at least two-thirds over the last year. Pfizer, one of the biggest pharmaceutical companies in the world, has dropped around a third.

https://www.reuters.com/business/healthcare-pharmaceuticals/falling-demand-covid-boosters-puts-price-hikes-table-2022-10-20/

<< Previous

Bullboard Posts

Next >>

A guide to understanding technical analysis for small-cap stocks